Treatment paradigms for small-volume, low-grade prostate cancer (PCa) are currently moving away from radical treatments. The recent controversial US preventative task force report ([@bib15]) giving PSA screening a 'D\' rating, prompted by the results from the PLCO and ERSP trials, has highlighted the issues associated with overdiagnosis and overtreatment of PCa. In follow-up of over 3,500 patients across seven active surveillance (AS) case series, the cancer-specific survival for the cohort is 99.7% ([@bib6]), though median follow-up remains relatively short (2--7 years). Active surveillance has emerged as a viable management option and should be offered to patients with low-risk cancer ([@bib21]; [@bib20]).

There are many different inclusion criteria for AS published in the literature. While all are variations on the model developed by [@bib10], the discrepancies between them reflect the uncertainty in appropriate cutoffs to distinguish indolent from high-risk cancer. In addition, regional differences in the underlying prevalence of PSA testing in the community alters the pre-test probability for high-risk disease ([@bib17]) in defined 'low-risk\' cohorts, which potentially interferes with the performance of selection rules when applied to populations distinct from which they were generated.

In our study, we examine application of AS selection rules to a combined Australian, British and Canadian group of patients who underwent radical prostatectomy (RP). Our primary objective was to document the proportion of pathological reclassification from prostate biopsy to RP. Secondary aims included analysis for predictors of high-risk disease and creation of a predictive model to assist with selection of men suitable for AS.

Materials and Methods
=====================

Pooled prospectively collected data from Addenbrooke\'s Hospital, Cambridge, United Kingdom (2005--2010); The Vancouver Prostate Centre, Canada (1995--2010); and the Australian Prostate Cancer Centre at Epworth, Melbourne, Australia (2003--2010) were retrospectively analysed. All patients had their RP specimens discussed at centralised multidisciplinary meetings and evaluated by dedicated genitourinary pathologists. Cambridge and Vancouver had routine centralised review of biopsies. Ethics approval in all three centres covers the use of collected clinical information for prognostic studies.

A summary of the literature review for published inclusion criteria used for AS is shown in [Table 1](#tbl1){ref-type="table"} ([@bib11]; [@bib31]; [@bib8]; [@bib13]; [@bib30]; [@bib24]; [@bib1]). In selecting which AS criteria to apply to our series, we used the University of Toronto criteria, described by [@bib13], from the first protocol-based AS prospective study and those published from the Prostate Cancer Research International: Active Surveillance (PRIAS) originating from the ERSPC ([@bib29]). Our cohort did not contain data for the amount of cancer present in a biopsy core (length or percentage) as only Cambridge consistently recorded this in their database so the PRIAS criteria were the strictest applicable to our data set.

Patients treated by means of RP who had preoperative parameters appropriate for inclusion for AS per these criteria had final pathology analysed for reclassification rates of upstaging, defined as ⩾pT3, or upgrading, defined as Gleason sum 7--10. Gleason 7 disease was subdivided into 3+4 and 4+3 groups. High-risk disease was defined as ⩾pT3 and/or Gleason sum ⩾8. CAPRA-S scores, a validated postsurgical score to predict PCa recurrence using pre-treatment and pathological data, for risk stratification were also calculated ([@bib6]). Lymph node involvement was not analysed, as across all centres there was no consistent policy regarding the performance of a pelvic lymph node dissection in patients with low-risk disease, and hence data collection was poor.

Differences between groups of continuous variables were determined by Mann--Whitney *U* or Kruskal--Wallis ANOVA. Pearson\'s *χ*^2^ or Fisher\'s exact test was used to determine differences between groups of categorical variables. To identify predictors of high-risk disease in patients selected for AS, logistic regression models were fitted, including parameters age, PSA, PSAD, clinical stage, number of biopsy cores taken, number of positive biopsy cores and centre of treatment as individual terms. Statistical analyses were performed using SPSS version 18.0 (IBM Corporation, Armonk, NY, USA), and all tests were two-sided with significance assumed at *P*\<0.05 unless otherwise stated.

To generate a clinically usable tool that predicted the presence of high-risk disease in the Cambridge cohort that met the Toronto criteria, all factors found to be significant in multivariate analysis were considered and the most parsimonious model generated from these. Patients were randomly assigned 70:30 to a learning and evaluation cohort. Logistic regression analysis was then performed using all available potential predictors of high-risk disease in the learning cohort, and a nomogram of the resulting equation generated using Orange (<http://orange.biolab.si> V2.0b, accessed 5 August 2011). The discriminative ability of our nomogram to predict high-risk disease was characterised by generating receiver operating characteristic curves based on the predicted probabilities of the evaluation cohort. A Loess calibration plot was used to assess the performance of our model across the entire range of predicted values, as the tool may have excellent overall accuracy but may not perform well in a specific range of predicted probabilities. A two-component (calibration and AUC calculation) decomposition Brier score was calculated, with a lower Brier score indicating better discriminant properties ([@bib9]).

Results
=======

Of the 2329 patients that had RP, 800 patients met the Toronto criteria for AS, and this number was reduced to 410 patients when the stricter PRIAS criteria were applied. The preoperative characteristics for these two groups are shown, overall and by treatment centre, in [Tables 2a](#tbl2a){ref-type="table"} and [2b](#tbl2b){ref-type="table"}. The pathology results from RP, including proportions reclassified and final risk group, also divided by treatment centre, are shown in [Tables 3a](#tbl3a){ref-type="table"} and [b](#tbl3b){ref-type="table"}. Overall, for those satisfying the Toronto criteria, 50.6% were upgraded to GS ⩾7 and 17.6% upstaged to pT3/4. The reclassification rates for the PRIAS group were 40.5% and 12.4%, respectively. For both groups, the majority of GS upgrading consisted of 3+4 disease (Toronto=84% and PRIAS=79%). In Cambridge, there was a relatively high rate of pT3a disease in the Toronto criteria group (26%) that decreased with PRIAS criteria (14%). Melbourne had a relatively high rate of Gleason 7 disease in final pathology for both the Toronto and PRIAS criteria groups (61 and 52%).

Given that study periods at different centres were different, to account for changes in biopsy technique, pathological interpretation and treatment patterns with time, we repeated the analysis in a restricted cohort (year ⩾2003 and total number of cores taken at biopsy ⩾8) more reflective of contemporary practice. Results of this subanalysis for the Toronto and PRIAS inclusion criteria are shown in [Table 4](#tbl4){ref-type="table"} and were similar to the initial overall analysis with similar proportions of GS upgrading (49.4% Toronto, 41% PRIAS) and pT3/4 upstaging (Toronto 17.9% and PRIAS 11.3%).

Using standard reported clinico-pathological variables, we were unable to derive a more accurate model that predicted indolent disease than the PRIAS criteria. However, we were able to identify significant predictors for high-risk disease ([Table 5a](#tbl5a){ref-type="table"}) by multivariate logistic regression analysis. For patients meeting the Toronto criteria, increasing age, number of positive cores, the presence of palpable disease as well as the centre of diagnosis were all significant predictors of the presence of high-risk disease; whereas for patients meeting the more stringent PRIAS criteria, only increasing PSA and the presence of palpable disease were significant. Total number of cores taken was analysed and not predictive.

A number of subgroup analyses were undertaken to search for predictors of more advanced disease. Examining for cancer present in a biopsy core (percentage) as a predictor in only the Cambridge cohort did not yield a significant result. Repeating multivariate logistic regression analyses, limited by year of surgery (⩾2003) and number of biopsy cores taken (⩾8) for high-risk disease (⩾pT3 or Gleason sum ⩾8) or ⩾pT3 alone, demonstrated similar predictors to those found for the entire cohort. There were no significant predictors of primary Gleason pattern 4 (as opposed to Gleason sum 8) identified.

We were unable to generate a nomogram from the whole cohort data because of difficulties modelling sampling error. To account for sampling error, we used an index of prostate size to number of cores taken; however, this did not significantly improve the performance of the model. As the rate of pT3a was high in the Cambridge data, we performed logistic regression analysis to identify predictors of ⩾pT3a/GS⩾8 disease specifically for the Cambridge cohort alone ([Table 5b](#tbl5b){ref-type="table"}). When only Cambridge data were analysed for the nomogram, PSAD was more predictive than PSA. From this analysis, a nomogram ([Figure 1a](#fig1){ref-type="fig"}) was generated that predicts individual risk of high-risk disease in UK men who meet the Toronto criteria, based on age, PSA density, number of positive biopsy cores, and the presence or absence of palpable disease. The logistic regression equation for the nomogram is also included to facilitate future validation studies ([Figure 1b](#fig1){ref-type="fig"}).

Assessment of the nomogram to predict the presence of high-risk disease in a randomly selected evaluation cohort revealed reasonable accuracy (AUC of 0.72) ([Figure 2](#fig2){ref-type="fig"}). A calibration plot, comparing nomogram-predicted probabilities to actual proportions of high-risk disease, is shown in [Figure 3](#fig3){ref-type="fig"}. This shows that our nomogram underestimates the observed probability of high-risk disease. The two-component (calibration and AUC calculation) decomposition Brier score was 0.199. External validation for the nomogram generated from the Cambridge data, using Melbourne and Vancouver data, showed an AUC of 0.68 and 0.55, respectively.

Discussion
==========

It is clear that published inclusion criteria for AS ([Table 1](#tbl1){ref-type="table"}) vary in their stringency. The criteria at John Hopkins Medical Institute are the strictest but some centres elsewhere have accepted Gleason 7 (usually 3+4), PSA levels up to 15 ng ml^−1^ and all clinical T2 disease. Furthermore, not all centres use PSAD (⩽0.15--0.20), number of positive cores (⩽2, ⩽3 or 1/3 of total) and percentage (⩽20--50%) of single core involvement to enrol patients. It has been demonstrated previously ([@bib27]; [@bib5]; [@bib18]) that increases in stringency can decrease the rates of adverse pathological features but will also substantially decrease the number of men suitable for AS. Until the ProtecT trial reports ([@bib14]), we will not know the criteria that predict the most important outcome of AS, namely death from PCa.

Our paper reports combined results from the Australian, British and Canadian academic centres. These results are compared with the American (UCSF, *n*=331 ([@bib5])) and European (Milan and Hamburg, *n*=2455 and Milan, *n*=85 ([@bib27]; [@bib26])) cohorts, where the Toronto and PRIAS inclusion criteria were also used to select patients from a RP database. Applying the Toronto criteria, we found a higher than previously reported rate of Gleason score upgrading (50.6%) compared with Conti *et al* 31% and Suardi *et al* 38.1%. However, similar to previous reports, the majority of GS upgrading was 3+4 disease (84%) and this may not translate into a major clinical problem. The rate of upstaging (EPE/SVI) when using the Toronto criteria (17%) was similar to previous reports in the literature (14--15%). There was less upstaging and upgrading when using the stricter PRIAS criteria; however, our reclassification rates are markedly higher (upgrading 42.7% and upstaging 12.7%) compared with those previously reported by the Milan group (upgrading 7.1% and upstaging 2.4% [@bib27]). The results of our subanalysis, by year (⩽2003) and number of biopsy cores taken (⩾8), demonstrated similar predictors to those found for the entire cohort. This was not surprising given that the two cohorts with high rates of upstaging (Cambridge) and upgrading (Melbourne) were the most contemporary with higher median number of cores taken ([Tables 2a](#tbl2a){ref-type="table"} and [b](#tbl2b){ref-type="table"}).

Individually, each of our three centres has a relatively high rate of GS upgrading ([Table 4](#tbl4){ref-type="table"}, Cambridge 44%, Vancouver 47%, Melbourne 62%). Possible reasons for this include sampling error on biopsy, interobserver pathology variation between biopsy and RP reports and differing geographic population patterns of disease. The number of biopsy cores taken for each centre was: Cambridge (median=12, IQR10-12), Melbourne (median=10, IQR8-13) and Vancouver (median=8, IQR8-8). The standard extended core template for prostate biopsy consists of 10--12 cores, and hence particularly in Vancouver biopsy under-sampling could affect our results. To minimise biopsy sampling error, [@bib1] suggest immediate confirmatory biopsy before commencing AS. There may be inter-observer variation influencing the Melbourne data as ∼50% of biopsies are reported by community pathologists, whereas all RP specimens are read by two specialist uro-pathologists. In addition, most of the upgrading was predominantly Gleason 3+4 disease (84% of those upgraded ([@bib27])). Results for carefully selected men on AS with intermediate-risk disease (Gleason sum 7 or CAPRA score 3--5) have been published suggesting that within limited follow-up (4years) outcomes were similar to men with GS 3+3 disease ([@bib7]).

Cambridge had a high proportion of EPE in its Toronto criteria group (26% *vs* 12%, *P*\<0.001) compared with the other two centres. As pathology for biopsy and RP is centrally reviewed in Cambridge and an extended template used for biopsy, this high rate of pT3a disease could also be attributable to a low uptake of PSA testing in the United Kingdom. [@bib16] compared worldwide rates of PSA testing in 2005 and, allowing for lack of standardized data, found rates of PSA testing in the United Kingdom considerably lower than elsewhere. At a similar period of time (year 2000), the rate of PSA testing in the United Kingdom was 5.4 tests per 100 men per annum (men 45--84 years old) compared with the United States, 38% of black men and 31% of white men (⩾65 years); Italy, 26.9% men (⩾40 years); Australia, 23% men (40--70 years); and Canada ([@bib2]), 47.5% (⩾50 years).

The few previously published predictive tools for AS selection have focused on calculating likelihood of indolent, low-volume/low-grade or insignificant PCa rather than high-risk features ([@bib12]; [@bib23]; [@bib19]; [@bib25]; [@bib22]). Nakanishi *et al*\'s nomogram, using a cohort of 258 men from the Canada and the United States, is specific for men with a single-positive biopsy core and uses age, PSAD and tumour length in a core to predict indolent cancer ([@bib19]). Possibly having a single positive core is too stringent a criterion for a programme of AS. Kattan *et al* 's nomogram to predict small, moderately differentiated, confined tumours ([@bib12]) that was recently validated and updated ([@bib25]); however, its application is questionable as its data are based on sextant biopsies with most centres now performing 10--12 core biopsies. A nomogram generated from an Australian cohort was recently published ([@bib22]), and for multiple probability cutoffs predicting indolent PCa, they gave coexisting rates of high-risk disease. It is likely that in the future men will be selected for AS programmes only if they have an mp-MRI that does not demonstrate any other unsuspected cancers, possibly coupled with a limited template biopsy. The result of the PIVOT trial ([@bib32]) has demonstrated that for low-risk men, surgery offers limited advantages over watchful waiting, and AS programmes are likely to be at least as effective.

To our knowledge, there has not been a nomogram derived from the British data to assist with selection of patients for AS. From our Cambridge data, we generated a nomogram that predicts presence of high-risk disease in patients who satisfy the Toronto entry criteria for AS. Overall assessment of the performance of our nomogram was good (AUC 0.72 and two-component Brier score 0.199). However, the calibration plot suggests that our nomogram consistently underestimates the observed proportion of high-risk disease for nearly all predicted values. Unsurprisingly, the nomogram performed poorer when we used the Melbourne (AUC 0.68) and Vancouver (0.55) data to externally validate it. There is evidence that risk calculators are best applied to the population from which they are generated ([@bib3]). An ideal nomogram would also include information on previous biopsies, family history of significant CaP and results of MRI imaging; however, this was not present in our data set. Given the low rate of PSA testing in the United Kingdom and the high rate of upstaging in our Cambridge cohort, our nomogram would be a reasonable tool for counselling UK patients in regards to AS.

Our study has limitations. Being retrospective, data collected were reliant on individual centres\' protocols and they did not include all information on tumour volume. The use of additional criteria such as length or percentage of a single core involved might reduce the amount of reclassification, but would likely reduce the number of patients to whom AS could be offered. Data on lymph node status were lacking as lymph node dissection for low-risk disease was according to surgeon preference, and not consistently performed or recorded. Lack of follow-up data for cancer recurrence or death is significant, as having pathological features of advanced disease on biopsy does not necessarily translate to poorer outcomes after surgery. Using a surgical cohort includes unforeseen biases in patient selection not addressed in AS criteria, such as age, comorbidities, family history, patient anxiety for intervention, and findings on imaging or institutional bias towards type of treatment. The median age of our cohort (61 years) is younger than that reported by AS cohorts (65 years; [@bib4]; [@bib30]). Being a multicentre study, multiple pathologists reported biopsies and specimens, and the effect of inter-observer variation was not calculated. We also accept that, given that our study spanned a broad period of time, interpretive changes in pathological grading and clinical staging of PCa did occur ([@bib28]). Multiple surgeons performed the surgery though positive margin rates that were similar.

Conclusions
===========

Our study examined the rates of reclassification of men from Australia, Britain and Canada who underwent RP who initially would have been suitable for AS, as defined by the Toronto and PRIAS criteria. Compared with previously reported cohorts from Europe and North America using the same AS selection criteria, we found significantly higher rates of upgrading and upstaging.

Care must be used when applying AS criteria generated from one population to another distinct population. There is an onus on larger centres in individual countries to assess the performance of different criteria on their population before implementation in routine AS programmes and generate predictive tools from their own data sets. Use of increasingly stringent selection criteria may reduce reclassification but this must be balanced against the exclusion of a significant number of men from AS who may benefit from such an approach.

The acceptability of AS protocols would best be evaluated by ongoing prospective studies. The development of novel serum or tissue markers, and improved imaging to predict disease progression would help remove any uncertainties physicians and patients have with AS.
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![Nomogram to predict individual probability of high-risk PCa in UK men who meet the Klotz criteria. For a patient, each criteria (age, PSAD, number of positive cores and cT stage) translates to a number of points -- read off the top line. The total number of points then corresponds to a probability of finding high-risk PCa if RP is performed. Logistic regression equation for nomogram. Log(*p*/1-*p*)=−7.051+0.059(age in years)+0.537(PSAD in units of 0.1 ng ml cm^3^)+0.996(cT)+0.218(number of positive cores).](bjc2012400f1){#fig1}

![Receiver operating characteristic curve to assess performance of nomogram predicting probability of high-risk PCa in UK men satisfying Klotz AS criteria.](bjc2012400f2){#fig2}
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###### Published criteria for active surveillance

  **Institution**                    **Principal investigator**    **Clinical stage**   **PSA (ng ml**^**−1**^)        **Biopsy Gleason score**         **PSA density (ng ml**^**−1**^** ml**^**−1**^)   **No. of +ve cores**   **% of single core**
  ---------------------------------- ---------------------------- -------------------- ------------------------- ------------------------------------- ------------------------------------------------ ---------------------- ----------------------
  Royal Marsden                      Parker                              T1-T2                    ⩽15                            ⩽3+4                                        ---                           ⩽50% total cores             ---
  University of Toronto              Klotz                              T1c/T2a                   ⩽10                             ⩽6                                         ---                                 ---                    ---
  PRIAS                              Shroder                             T1c/T2                   ⩽10                             ⩽6                                        \<0.20                                ⩽2                    ---
  UCSF                               Carroll                             T1-T2                    ⩽10                             ⩽6                                         ---                         ⩽1/3 of total cores            ⩽50%
  MSK                                Eastham                             T1-T2a                   ⩽10                             ⩽6                                         ---                                  ⩽3                    ⩽50%
  University of Miami                Soloway                              ⩽T2                     ⩽10                             ⩽6                                         ---                                  ⩽2                    ⩽20%
  John Hopkins Medical Institution   Carter                               T1c                     ---             ⩽3, no pattern Gleason score 4 or 5                       ⩽0.15                                 ⩽2                    ⩽50%

Abbreviations: MSK=Memorial Sloan Kettering; PRIAS=Prostate Cancer Research International: Active Surveillance; PSA=prostate-specific antigen; UCSF=University of California, San Francisco.

###### Preoperative characteristics for patients suitable for AS according to the Toronto criteria -- by centre

                                    **Total**          **Cambridge**         **Melbourne**        **Vancouver**
  ---------------------------- ------------------- --------------------- --------------------- --------------------
  Years of data                    1995--2010           2005--2010            2003--2010            1995--2010
  *N* (total RP)                      2329                  700                   790                  839
  *N* (total AS)                   800 (34.3%)           267 (40%)             187 (31%)            190 (32%)
                                                                                                         
  *Age (years)*                                                                                          
   Median (IQR)                   61 (56.7−65)          61 (39−73)            60 (42−74)            61 (43−79)
                                                                                                         
  *PSA (ng ml^−1^)*                                                                                      
   Median (IQR)                   5.8 (4.7−7.4)        6.4 (0.5−10)          5.5 (0.3−10)          5.5 (0.5−10)
                                                                                                         
  *Clinical stage*                                                                                       
   cT1                             570 (71.3%)           206 (77%)             149 (80%)            109 (58%)
   cT2a                            230 (28.7%)           59 (23%)              38 (20%)              80 (42%)
                                                                                                         
  *PSA density*^a^                                                                                       
   Median (IQR)                 0.1 (0.086−0.151)   0.108 (0.011−0.816)   0.114 (0.014−0.315)   0.11 (0.012−0.371)
                                                                                                         
  *Biopsy cores taken*                                                                                   
   Median (range)                   10 (2−30)            12 (4−30)             11 (4−30)             8 (2−13)
                                                                                                         
  *Number of positive cores*                                                                             
   Median (IQR)                      2 (1−4)             2 (1−14)              3 (1−12)              2 (1−8)

###### Preoperative characteristics for patients suitable for AS according to the PRIAS criteria -- by centre

                                                   **Total**         **Cambridge**      **Melbourne**     **Vancouver**
  ------------------------------------------- ------------------- ------------------- ------------------ ----------------
  *N* (total RP)                                     2329                 700                790               839
  *N* (total AS)                                   410 (18%)           134 (19%)          114 (14%)         162 (19%)
                                                                                                                 
  *Age (years)*                                                                                                  
   Median (IQR)                                 60.5 (56.3--65)       62 (45--70)        59 (48--73)       62 (43--73)
                                                                                                                 
  *PSA (ng ml^−1^)*                                                                                              
   Median (IQR)                                  5.6 (4.3--7)        6.3 (2.7--10)      5.6 (0.3--10)     5.4 (1.5--0.4)
                                                                                                                 
  *Clinical stage*                                                                                               
   cT1                                             287 (70%)           109 (81%)           91 (80%)          87 (54%)
   cT2a                                            123 (30%)           25 (19%)            23 (20%)          75 (46%)
                                                                                                                 
  *PSA density*[a](#t2b-fn2){ref-type="fn"}                                                                      
   Median (IQR)                                0.1 (0.071--0.13)   0.99 (0.02--0.19)   0.1 (0.01--0.19)   0.1(0.01--0.2)
                                                                                                                 
  *Biopsy cores taken*                                                                                           
   Median (range)                              9 (2--24 -- IQR)       12 (6--24)          10 (3--17)        8 (2--12)
                                                                                                                 
  *Number of positive cores*                                                                                     
   Median (IQR)                                        1               1 (1--2)            2 (1--2)          2 (1--2)

Abbreviations: AS=active surveillance; IQR=interquartile range; PRIAS=Prostate Cancer Research International: Active Surveillance; PSA=prostate-specific antigen; RP=radical prostatectomy.

Not part of the original Klotz criteria but reported for comparison with Van den Bergh.

###### Pathological results, with upgrading and upstaging rates highlighted, from radical prostatectomy for patients suitable for the Toronto AS criteria

                              **Total (Toronto)**   **Cambridge**   **Melbourne**   **Vancouver**  ***P***
  -------------------------- --------------------- --------------- --------------- --------------- ---------
  *n*                                 800                280             248             272        
  Pathological GS                                                                                   
    ⩽ 6                           395 (47.8%)         157 (56%)       94 (38%)        144 (53%)    \<0.001
  *Upgrading*  7                  389 (48.6%)         117 (42%)       151 (61%)       121 (44%)     
     3+4                          340 (87.4%)         108 (92%)       133 (88%)       99 (82%)     0.049
     4+3                          49 (12.6%)           9 (8%)         18 (12%)        22 (18%)      
    8--10                           16 (2%)            6 (2%)          3 (1%)          7 (3%)       
                                                                                                    
  *pT*                                                                                              
    pT2                           659 (82.4%)         205 (73%)       216 (87%)       238 (88%)    \<0.001
                                                                                                    
  *Upstaging*                                                                                       
    pT3/4                         141 (17.6%)         75 (27%)        32 (13%)        34 (12%)      
     EPE                           136 (17%)          73 (26%)        30 (12%)        32 (12%)      
     SVI                            8 (1%)             2 (1%)          3 (1%)          3 (1%)       
                                                                                                    
  *Margins*                                                                                         
   Negative                       675 (84.4%)         239 (85%)       217 (88%)       219 (81%)    0.077
   Positive                       125 (15.6%)         41 (15%)        31 (12%)        53 (19%)      
                                                                                                    
  *Percent tumour (n=716)*                                                                          
   Median                              5                  5               3              10        \<0.001
   Range                             3--15              4--10          1.5--9           5--20       
                                                                                                    
  *Final risk group^a^*                                                                             
   Low                            362 (45.3%)         135 (48%)       91 (37%)        136 (50%)    \<0.001
   Intermediate                   286 (35.8%)         65 (23%)        123 (50%)       98 (36%)      
   High                            152 (19%)          80 (29%)        13 (13%)        38 (14%)      
                                                                                                    
  *CAPRA-S risk groups*                                                                             
   0--2                           629 (78.6%)        208 (77.9%)     152 (82.3%)     143 (75.3%)   0.42
   3--5                           165 (20.6%)        58 (21.7%)      34 (18.2%)      44 (23.2%)     
   ⩾6                              6 (0.8%)           1 (0.4%)        1 (0.5%)        3 (1.5%)      

###### Pathological results, with upgrading and upstaging rates highlighted, from radical prostatectomy for patients suitable for the PRIAS criteria

                                                    **Total (PRIAS)**   **Cambridge**   **Melbourne**   **Vancouver**  ***P***
  ------------------------------------------------ ------------------- --------------- --------------- --------------- ---------
  *n*                                                      410               134             114             162        
  Pathological GS                                                                                                       
    ⩽6                                                 235 (57.3%)        87 (65%)        53 (46%)        95 (58%)     0.005
  *Upgrading*  7                                       166 (40.5%)        44 (33%)        59 (52%)        63 (39%)      
     3+4                                               138 (83.1%)        40 (91%)        52 (88%)        46 (73%)     0.023
     4+3                                               28 (16.9%)          4 (9%)          7 (12%)        17 (27%)      
    8--10                                               9 (2.2%)           3 (2%)          2 (2%)          4 (3%)       
                                                                                                                        
  *pT*                                                                                                                  
    pT2                                                359 (87.6%)        115 (86%)       104 (91%)       140 (86%)    0.43
                                                                                                                        
  *Upstaging*                                                                                                           
    pT3/4                                              51 (12.4%)         19 (14%)         10 (9%)        22 (14%)      
     EPE                                               48 (11.7%)         19 (14%)         9 (8%)         20 (12%)     0.27
     SVI                                                 4 (1%)            0 (0%)          1 (1%)          3 (2%)       
                                                                                                                        
  *Margins*                                                                                                             
   Negative                                            364 (88.8%)        122 (91%)       103 (90%)       139 (86%)    0.3
   Positive                                            46 (11.2%)          12 (9%)        11 (10%)        23 (14%)      
                                                                                                                        
  *Percent tumour* (*n*=367)                                                                                            
   Median                                                   5                 5               2              10        \<0.001
   Range                                                  2--10            0.2--80         0.3--37          1--70       
                                                                                                                        
  *Final risk group[a](#t3b-fn2){ref-type="fn"}*                                                                        
   Low                                                 219 (53.4%)        79 (59%)        52 (46%)        88 (54%)     0.014
   Intermediate                                        133 (32.4%)        33 (25%)        51 (45%)        49 (30%)      
   High                                                53 (14.1%)         22 (16%)         11 (9%)        25 (16%)      
                                                                                                                        
  *CAPRA-S risk groups*                                                                                                 
   0--2 (low)                                          346 (84.4%)       112 (89.6%)      76 (87%)        77 (79%)     0.2
   3--5                                                60 (14.6%)         12 (9.6%)       10 (12%)        20 (20%)      
   ⩾6                                                    4 (1%)           1 (0.8%)         1 (1%)          1 (1%)       

Abbreviations: AS=active surveillance; CAPRA=Cancer of the Prostate Risk Assessment Post-Surgical Score; GS=Gleason sum; PRIAS=Prostate Cancer Research International: Active Surveillance.

Risk group patterned on D′Amico system with pT and Gleason sum from radical prostatectomy (instead of cT and biopsy Gleason sum). Risk groups 0--2=low; 3--5=intermediate; ⩾6=high.

###### Data (combined three centres) restricted to year ⩾2003 and total number of biopsy cores ⩾8

  ------------------------------------------ ---------------------- --------------------- ---------
                                              **Toronto criteria**   **PRIAS criteria**   ***P***
  Years of data                                    2003--2010            2003--2010        
  *N* (total AS)                                      644                    310           
  *Age (years)*                                                                            
   Median (IQR)                                   61 (57--65)            61 (57--65)      0.55
                                                                                           
  *PSA (ng ml^−1^)*                                                                        
   Median (IQR)                                  5.8 (4.7--7.4)        5.6 (4.4--7.0)     0.018
                                                                                           
  *Clinical stage*                                                                         
   cT1                                            467 (72.5%)            232 (74.8%)       
   cT2a/cT2                                       177 (27.5%)            78 (25.2%)       0.45
                                                                                           
  *PSA density[a](#t4-fn2){ref-type="fn"}*                                                 
   Median (IQR)                               0.111 (0.082--0.147)   0.098 (0.07--0.127)  \<0.001
                                                                                           
  *Biopsy cores taken*                                                                     
   Median (range)                                  10 (8--12)            10 (8--12)        
                                                                                           
  *Number of positive cores*                                                               
   Median (IQR)                                     2 (1--4)              1 (1--2)        0.48
                                                                                           
  *Centre (n, %)*                                                                          
   Cambridge                                      267 (41.5%)            125 (40.3%)      0.8
   Vancouver                                       190 (29%)             87 (28.1%)        
   Melbourne                                       187 (29%)             98 (31.6%)        
                                                                                           
  *Prostatectomy Gleason score*                                                            
   ⩽6                                             311 (48.3%)            176 (56.8%)      0.24
   7                                              318 (49.4%)             127 (41%)        
    *3+4*                                        *273 (85.8%)*          *102 (80.3%)*      
    *4+3*                                         *45 (14.2%)*          *25 (19.7%)*       
   8--10                                           15 (2.3%)              7 (2.2%)         
                                                                                           
  *pT*                                                                                     
   pT2                                            529 (82.1%)            275 (88.7%)      0.024
   pT3/4                                          115 (17.9%)            35 (11.3%)        
                                                                                           
  *EPE*                                                                                    
   No                                             533 (82.8%)            277 (89.4%)      0.008
   Yes                                            111 (17.2%)            33 (10.6%)        
                                                                                           
  *SVI*                                                                                    
   No                                             637 (98.9%)             307 (99%)       0.87
   Yes                                              7 (1.1%)               3 (1%)          
  ------------------------------------------ ---------------------- --------------------- ---------

Abbreviations: AS=active surveillance; IQR=interquartile range; PRIAS=Prostate Cancer Research International: Active Surveillance; PSA=prostate-specific antigen. PSA density

=not part of original Klotz criteria but reported for comparison to Van den Bergh.

###### Predictors of high-risk(^a^) disease for combined three centres, the Toronto and PRIAS selection criteria for AS groups

                              **Toronto AS criteria**  **PRIAS criteria**                                    
  -------------------------- ------------------------- -------------------- --------- -------- ------------- ---------
                                      **OR**           **95% CIs**          ***P***    **OR**  **95% CIs**   ***P***
  Age                                  1.04            1.01--1.07           0.02        1.02   0.97--1.07    0.47
  PSA                                  1.08            0.98--1.19           0.1         1.15   1.01--1.31    0.043
  cT                                   1.54            1.01--2.34           0.045       1.85   1.03--3.32    0.04
  Total no. of cores taken             0.94            0.88--1.01           0.085       0.95   0.87--1.04    0.25
  No. of positive cores                1.25            1.14--1.37           \<0.001     0.91   0.51--1.61    0.75
  Centre                                                                                                      
   Vancouver                             1                                               1                    
   Cambridge                           2.85            1.68--4.84           \<0.001     1.55   0.71--3.38    0.27
   Melbourne                           1.03            0.59--1.79           0.91        0.76   0.34--1.7     0.51

###### Predictors of high-risk([a](#t5b-fn2){ref-type="fn"}) disease for the Cambridge cohort, Toronto AS selection criteria.

                   **OR**   **95% CIs**   ***P***   
  ---------------- -------- ------------- --------- -------
  Age              1.06     1             1.13      0.049
  PSAD             1.71     1.03          2.83      0.037
  Ct               2.71     1.2           6.12      0.017
  Positive cores   1.24     1.06          1.46      0.008

Abbreviations: AS=active surveillance; CI=confidence interval; OR=odds ratio; PRIAS=Prostate Cancer Research International: Active Surveillance; PSAD=PSA density.

High-risk disease defined as ⩾pT3 and/or Gleason sum ⩾8.
